Logo

BEAM

Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc. • NASDAQ
$25.33 ▲ 1.20% (+0.30)
Market Cap $2.57 B
52w High $35.25
52w Low $13.53
Dividend Yield 0%
P/E -5.74
Volume 837.30K
Outstanding Shares 101.47M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $9.698M ▲ $26.74M ▼ $-112.728M ▼ -1.162K% ▲ $-1.1 ▼ $-107.168M ▲
Q2-2025 $8.466M ▲ $26.859M ▼ $-102.291M ▲ -1.208K% ▲ $-1 ▲ $-114.613M ▼
Q1-2025 $7.47M ▼ $27.94M ▼ $-109.27M ▼ -1.463K% ▼ $-1.24 ▼ $-113.758M ▼
Q4-2024 $30.067M ▲ $28.66M ▲ $-90.354M ▲ -300.509% ▲ $-1.09 ▲ $-94.594M ▲
Q3-2024 $14.269M $26.515M $-96.668M -677.469% $-1.17 $-101.029M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $1.075B ▼ $1.311B ▼ $345.079M ▲ $966.002M ▼
Q2-2025 $1.15B ▼ $1.391B ▼ $344.344M ▲ $1.047B ▼
Q1-2025 $1.22B ▲ $1.467B ▲ $343.784M ▼ $1.123B ▲
Q4-2024 $850.74M ▼ $1.104B ▼ $370.279M ▼ $733.545M ▼
Q3-2024 $925.757M $1.171B $380.05M $791.317M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-112.728M ▼ $-81.479M ▼ $65.655M ▲ $1.675M ▲ $-14.172M ▲ $-86.49M ▼
Q2-2025 $-102.291M ▲ $-76.45M ▲ $-170.411M ▼ $1.109M ▼ $-245.752M ▼ $-79.586M ▲
Q1-2025 $-109.27M ▼ $-103.884M ▼ $-125.089M ▼ $473.379M ▲ $244.406M ▲ $-106.949M ▼
Q4-2024 $-90.354M ▲ $-76.365M ▲ $126.28M ▲ $3.444M ▲ $53.359M ▲ $-79.335M ▲
Q3-2024 $-96.668M $-88.125M $24.698M $1.262M $-62.165M $-89.702M

Five-Year Company Overview

Income Statement

Income Statement Beam is still very much a research‑stage biotech company, and its income statement reflects that. Revenue is minimal and irregular, coming mostly from collaborations rather than product sales, so it does not yet provide meaningful support for operations. The company consistently reports sizable operating losses, driven mainly by heavy spending on research, clinical development, and supporting infrastructure. While losses have fluctuated from year to year, the overall pattern is clear: Beam is investing aggressively ahead of any commercial launch, and profitability is not in sight until one or more programs succeed and reach the market.

Balance Sheet

Balance Sheet Beam’s balance sheet looks typical for an early‑stage biotech that has raised substantial capital. Total assets are high relative to its size, and a large portion of those assets is cash and investments, although cash has been trending down as it funds operations. Debt levels are modest and appear manageable compared with the company’s equity base and cash resources. Shareholders’ equity is solid, indicating that the company has primarily funded itself through equity raises rather than heavy borrowing. Overall, the balance sheet provides a cushion to support multi‑year R&D, but that cushion is gradually being used up.

Cash Flow

Cash Flow Cash flow statements show that Beam consumes cash rather than generates it. Operating cash flow has been negative in most years and became more heavily negative recently, reflecting rising spending on clinical trials, platform development, and organizational build‑out. Free cash flow is also clearly negative, although capital spending on facilities and equipment is relatively modest. The result is a steady drawdown of the company’s cash balance. According to the provided information, management believes the existing cash runway extends into the second half of the decade, but that assumes continued discipline and no major setbacks or cost spikes.

Competitive Edge

Competitive Edge Beam’s competitive position rests on its differentiated base editing technology, which is designed to make precise DNA changes without cutting both strands of the DNA helix. This approach aims to be more targeted and potentially safer than traditional CRISPR “cut and paste” systems, which is a meaningful selling point for regulators, partners, and patients if the safety data hold up. The company has built a layered moat: a strong intellectual property portfolio around base editing, an integrated platform that includes delivery technologies and in‑house manufacturing, and early clinical proof‑of‑concept in *in vivo* base editing. At the same time, the competitive field is crowded and dynamic, with many other gene editing players pursuing overlapping indications and technologies. Beam’s success will depend on translating its technical edge into clear clinical advantages—better safety, durable benefit, or superior convenience—before rivals establish their own standards of care.

Innovation and R&D

Innovation and R&D Beam is heavily innovation‑driven, with its financial losses largely reflecting sustained investment in R&D. Its base editing platform is at the heart of this effort, aiming to rewrite single DNA letters with high precision across a wide range of diseases. The pipeline is diversified across both *ex vivo* and *in vivo* approaches. Programs include treatments for sickle cell disease, liver‑based genetic disorders like alpha‑1 antitrypsin deficiency and glycogen storage disease, and a non‑genotoxic conditioning platform (ESCAPE) meant to make stem cell transplants safer. The company has also moved into multiplex editing for oncology. Recent and upcoming clinical readouts—particularly for BEAM‑101 and BEAM‑302—and the reported first‑in‑human *in vivo* base editing data are key value drivers and will strongly influence perceptions of the platform’s safety and effectiveness. Partnerships and the build‑out of internal manufacturing further support Beam’s ability to innovate at scale, but they also lock in a high ongoing R&D and infrastructure cost base.

Summary

Beam Therapeutics is an early‑stage, high‑science biotech where the story is almost entirely about future potential rather than current financial performance. The company has negligible recurring revenue and significant, persistent losses as it funds a broad portfolio of base editing programs and platform investments. The balance sheet currently provides a meaningful financial buffer, with substantial cash and only modest debt, giving Beam time to generate decisive clinical data. However, the cash burn is material, and the company remains dependent on capital markets or partnerships over the long term unless one or more therapies reach commercialization. Strategically, Beam’s strengths lie in its differentiated base editing technology, robust IP, early *in vivo* proof‑of‑concept, and integrated manufacturing and delivery capabilities. Its main risks center on clinical, regulatory, and execution uncertainty, the intense competitive landscape in gene editing, and the need to continually fund operations until durable revenue emerges. Overall, Beam represents a classic high‑risk, high‑uncertainty biotech profile: financially loss‑making today but potentially very impactful if its base editing platform proves both safe and effective across multiple indications.

NEWS

November 12, 2025 · 7:00 AM UTC

Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference

Read more

November 4, 2025 · 7:00 AM UTC

Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates

Read more

November 3, 2025 · 9:00 AM UTC

Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

Read more

September 17, 2025 · 7:00 AM UTC

JIM BEAM AND THE CADILLAC FORMULA 1® TEAM ANNOUNCE GLOBAL PARTNERSHIP, FUELING A VISION TO REACH NEW AUDIENCES

Read more